Bavarian Nordic (OTCMKTS:BVNRY) Sees Strong Trading Volume - Here's Why

Key Points

• Bavarian Nordic shares experienced a significant increase in trading volume, rising 32% to 10,452 shares on a recent Wednesday.
• The company reported quarterly earnings of $0.13 per share and revenue of $189.89 million, with a net margin of 21.11%.
• Bavarian Nordic specializes in life-saving vaccines, including those for smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) shares saw strong trading volume on Wednesday . 10,452 shares changed hands during trading, an increase of 32% from the previous session's volume of 7,905 shares.The stock last traded at $12.25 and had previously closed at $12.30.

Bavarian Nordic Stock Up 0.1%

The company has a market cap of $2.92 billion, a PE ratio of 15.43 and a beta of 1.36. The firm's fifty day simple moving average is $9.88 and its 200-day simple moving average is $8.63.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $189.89 million during the quarter. Bavarian Nordic had a return on equity of 11.89% and a net margin of 21.11%. On average, analysts predict that Bavarian Nordic will post 0.67 earnings per share for the current year.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.